# Axcynsis Therapeutics Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axcynsis-therapeutics-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.axcynsis.com
- Total disclosed funding: $15M
- Latest round: Series A (Jun 3, 2023)
- Investors on record: 1

## About

In 2022, the company was founded by Dr. Zou Bin, who also serves as the CEO of the company, under the name Tetris Therapeutics. Two months later, the company changed its name into Axcynsis Therapeutics, and officially opened its office in Singapore in September. In 2023, the company opened its office in Shanghai, China.

The company operates as a platform focusing on developing antibody-X conjugate (AXC) therapies to treat cancer. The core technologies the company utilizes are Antibody Discovery Technology, LP (Linker + Payload) Technology, and Conjugation Technology. As of 2023, the company has four pipelines under development, three (AT – 01, AT - 03, AT - 04) in the optimization stage, and one in discovery stage (AT - 00).

## Funding rounds

- Series A, Jun 3, 2023, $15M — Trinity Innovation Bioventure Singapore

## Investors

- Trinity Innovation Bioventure Singapore (https://capitalatlas.ai/funds/trinity-innovation-bioventure-singapore) — Series A